Using serum samples of acute and convalescent COVID-19 patients, we analyzed their neutralizing, FcγR-, and C1q-mediated ADE activities in vitro and found evidence of both types of ADE that counteracted neutralizing activities depending on the concentrations of antibodies. The gene discussed is FCGR2A; the disease is COVID-19.